MXPA05007379A - Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos. - Google Patents

Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.

Info

Publication number
MXPA05007379A
MXPA05007379A MXPA05007379A MXPA05007379A MXPA05007379A MX PA05007379 A MXPA05007379 A MX PA05007379A MX PA05007379 A MXPA05007379 A MX PA05007379A MX PA05007379 A MXPA05007379 A MX PA05007379A MX PA05007379 A MXPA05007379 A MX PA05007379A
Authority
MX
Mexico
Prior art keywords
retching
vomiting
combination
subject
treating nausea
Prior art date
Application number
MXPA05007379A
Other languages
English (en)
Spanish (es)
Inventor
Cheryl L Miller
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Publication of MXPA05007379A publication Critical patent/MXPA05007379A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Dental Preparations (AREA)
MXPA05007379A 2003-01-13 2004-01-13 Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos. MXPA05007379A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44007603P 2003-01-13 2003-01-13
US49247803P 2003-08-04 2003-08-04
PCT/US2004/000809 WO2004062624A2 (en) 2003-01-13 2004-01-13 Method of treating nausea, vomiting, retching or any combination thereof

Publications (1)

Publication Number Publication Date
MXPA05007379A true MXPA05007379A (es) 2006-02-10

Family

ID=32718144

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007379A MXPA05007379A (es) 2003-01-13 2004-01-13 Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.

Country Status (14)

Country Link
US (3) US20040147510A1 (enExample)
EP (1) EP1567163B1 (enExample)
JP (1) JP2006516977A (enExample)
KR (1) KR20050094843A (enExample)
AT (1) ATE359079T1 (enExample)
AU (1) AU2004204827B2 (enExample)
BR (1) BRPI0406748A (enExample)
CA (1) CA2512022A1 (enExample)
DE (1) DE602004005814T2 (enExample)
ES (1) ES2285407T3 (enExample)
MX (1) MXPA05007379A (enExample)
NZ (1) NZ541009A (enExample)
PL (1) PL378369A1 (enExample)
WO (1) WO2004062624A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
AU2003259373B2 (en) * 2002-08-29 2006-03-09 Dynogen Pharmaceuticals, Inc. New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine
EP1558081A4 (en) * 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc METHOD FOR THE TREATMENT OF FUNCTIONAL ENDURANCE DISEASES
DE602004005814T2 (de) * 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
WO2005007600A2 (en) * 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
EP1831173B1 (en) * 2004-12-17 2011-01-26 Janssen Pharmaceutica NV Tetrahydroisoquinoline compounds for treatment of cns disorders
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007005780A2 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
WO2007090113A2 (en) * 2006-02-01 2007-08-09 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
WO2007120445A1 (en) * 2006-03-31 2007-10-25 Dynogen Pharmaceuticals, Inc. SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES
WO2007131070A2 (en) * 2006-05-04 2007-11-15 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
WO2008038106A1 (en) * 2006-09-27 2008-04-03 Orchid Chemicals & Pharmaceuticals Limited Venlafaxine extended release formulations
SI2432467T1 (en) * 2009-05-20 2018-06-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) ANTAGONIST RECEPTOR SEROTONINA 5-HT3 FOR THE USE IN THE TREATMENT OF LEASE VESTIBULAR DISEASES
KR102270521B1 (ko) 2013-03-14 2021-06-30 레드힐 바이오파마 엘티디 구토억제 서방형 고체 제형
UA121209C2 (uk) 2014-03-11 2020-04-27 Редгіл Байофарма Лтд. Тверді лікарські форми ондансетрону з пролонгованим вивільненням для лікування симптомів нудоти, блювання або діареї
ES2975016T3 (es) 2016-04-14 2024-07-02 Sensorion (+)-Azasetrón para uso en el tratamiento de trastornos del oído
WO2022015628A2 (en) * 2020-07-15 2022-01-20 St. Jude Children's Research Hospital, Inc. Obese ferret model and methods of establishing and using the same
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023164132A1 (en) * 2022-02-25 2023-08-31 Neuraxis, Inc. Auricular nerve field stimulation device and methods for using the same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107244A (en) * 1870-09-13 Improved manner of treating- cod-liver and castor-oils
US36500A (en) * 1862-09-23 Joseph banks
US203055A (en) * 1878-04-30 Improvement in carpet-stretchers
US254172A (en) * 1882-02-28 Half to laweence
US48874A (en) * 1865-07-18 Improved extension door-knobs
US44450A (en) * 1864-09-27 Improvement in ore-crushers
US36549A (en) * 1862-09-23 Improvement in caps
US254171A (en) * 1882-02-28 Car-axle box
US4225407A (en) * 1979-04-04 1980-09-30 The Dow Chemical Company Cathodic electrodeposition of polymers onto a conductive surface
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
DE3689974T2 (de) * 1985-03-14 1994-11-03 Beecham Group Plc Arzneimittel zur Behandlung von Emesis.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
ES2059491T3 (es) * 1987-06-29 1994-11-16 Duphar Int Res Derivados de indol con anillos condensados.
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
WO1993000074A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
GB9214184D0 (en) 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
WO1997005129A1 (en) * 1995-07-28 1997-02-13 Dainippon Pharmaceutical Co., Ltd. (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
DE69725345T2 (de) * 1996-02-15 2004-08-19 Janssen Pharmaceutica N.V. Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden
DK0975327T3 (da) * 1997-04-18 2003-10-20 Janssen Pharmaceutica Nv Anvendelse af 5HT3-antagonister til befordring af tarmudskylning
JPH10298078A (ja) 1997-05-06 1998-11-10 Mitsubishi Chem Corp 抗不安薬
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
ES2157107T3 (es) * 1997-09-16 2001-08-01 Solvay Pharm Gmbh Uso de moxonidina para el tratamiento del dolor neuropatico.
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6376550B1 (en) * 1999-02-09 2002-04-23 Asta Medica Ag Pharmaceutical compositions containing tramadol for migraine
ES2327600T3 (es) * 1999-02-18 2009-11-02 Novasearch Ag Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas.
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
EP1091748A2 (en) * 1999-04-12 2001-04-18 University of Madras A pharmaceutical formulation useful for the treatment of hepatitis b, hepatitis c and other viral infections of the liver and a process for its preparation
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE60019473T2 (de) * 1999-07-01 2006-02-23 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0112494D0 (en) 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
EP1465629B1 (en) 2002-01-18 2007-03-14 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
WO2003077897A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
DE60326585D1 (de) 2002-07-10 2009-04-23 Dynogen Pharmaceuticals Inc 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidin bei der behandlung von funktionalen darmstörungen
AU2003259373B2 (en) * 2002-08-29 2006-03-09 Dynogen Pharmaceuticals, Inc. New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine
WO2004058353A2 (en) 2002-12-24 2004-07-15 Paradigm Therapeutics Ltd. Therapeutic use of selective noradrenaline reuptake inhibitors
DE602004005814T2 (de) * 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
EP1558081A4 (en) * 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc METHOD FOR THE TREATMENT OF FUNCTIONAL ENDURANCE DISEASES

Also Published As

Publication number Publication date
PL378369A1 (pl) 2006-04-03
US20040254171A1 (en) 2004-12-16
US7094786B2 (en) 2006-08-22
WO2004062624A3 (en) 2005-04-07
AU2004204827A1 (en) 2004-07-29
KR20050094843A (ko) 2005-09-28
CA2512022A1 (en) 2004-07-29
NZ541009A (en) 2007-09-28
EP1567163A4 (en) 2006-01-18
US20040254172A1 (en) 2004-12-16
BRPI0406748A (pt) 2005-12-20
EP1567163A2 (en) 2005-08-31
AU2004204827B2 (en) 2006-06-29
WO2004062624A2 (en) 2004-07-29
EP1567163B1 (en) 2007-04-11
US20040147510A1 (en) 2004-07-29
DE602004005814T2 (de) 2008-01-10
ES2285407T3 (es) 2007-11-16
JP2006516977A (ja) 2006-07-13
ATE359079T1 (de) 2007-05-15
DE602004005814D1 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
MXPA05007379A (es) Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
MXPA05007381A (es) Metodo para el tratamiento de transtornos funcionales del intestino.
TW200637831A (en) Triazole compounds that modulate Hsp90 activity
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
TW200738234A (en) Triazole compounds that modulate HSP90 activity
WO2004103288A3 (en) Method of preventing recurrent miscarriages
GEP20104908B (en) Use of palonosetron treating post-operative nausea and vomiting
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
PL1664016T3 (pl) Środki terapeutyczne przydatne do leczenia bólu
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2006116626A3 (en) Methods and compositions for treating pain
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
IL180551A0 (en) Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
MX340217B (es) Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon.
TW200639159A (en) Treatment of pain
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2004110392A3 (en) Compositions and methods for treating coronavirus infection and sars
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights